DK3285772T3 - En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom - Google Patents

En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom Download PDF

Info

Publication number
DK3285772T3
DK3285772T3 DK16719356.4T DK16719356T DK3285772T3 DK 3285772 T3 DK3285772 T3 DK 3285772T3 DK 16719356 T DK16719356 T DK 16719356T DK 3285772 T3 DK3285772 T3 DK 3285772T3
Authority
DK
Denmark
Prior art keywords
trifluorethylquinoline
sjögren
analogue
syndrome
treatment
Prior art date
Application number
DK16719356.4T
Other languages
English (en)
Inventor
Rodger Anthony Allen
Francesca Barone
William Anthony Fahy
Saba Nayar
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Application granted granted Critical
Publication of DK3285772T3 publication Critical patent/DK3285772T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16719356.4T 2015-04-21 2016-04-20 En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom DK3285772T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (1)

Publication Number Publication Date
DK3285772T3 true DK3285772T3 (da) 2020-01-13

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16719356.4T DK3285772T3 (da) 2015-04-21 2016-04-20 En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom

Country Status (27)

Country Link
US (1) US10493074B2 (da)
EP (1) EP3285772B1 (da)
JP (1) JP6721606B2 (da)
KR (1) KR102627370B1 (da)
CN (1) CN107530344B (da)
AR (1) AR105552A1 (da)
AU (1) AU2016251236B2 (da)
BR (1) BR112017020591B8 (da)
CA (1) CA2981631C (da)
CL (1) CL2017002669A1 (da)
CO (1) CO2017010573A2 (da)
CY (1) CY1122572T1 (da)
DK (1) DK3285772T3 (da)
EA (1) EA032432B1 (da)
ES (1) ES2763335T3 (da)
GB (1) GB201506786D0 (da)
HR (1) HRP20192273T1 (da)
HU (1) HUE047162T2 (da)
IL (1) IL254766B (da)
LT (1) LT3285772T (da)
MX (1) MX2017013148A (da)
MY (1) MY192972A (da)
PL (1) PL3285772T3 (da)
PT (1) PT3285772T (da)
SG (1) SG11201707789YA (da)
SI (1) SI3285772T1 (da)
WO (1) WO2016170014A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031569B (zh) * 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
JP5527761B2 (ja) * 2007-03-23 2014-06-25 アムジエン・インコーポレーテツド 複素環化合物およびそれの使用
JP5889795B2 (ja) * 2009-11-05 2016-03-22 ライゼン・ファーマシューティカルズ・エスアー 新規キナーゼモジュレーター
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
WO2014201409A1 (en) * 2013-06-14 2014-12-18 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
AU2016251236A1 (en) 2017-11-09
CA2981631C (en) 2023-02-21
CL2017002669A1 (es) 2018-05-11
CN107530344B (zh) 2020-03-17
KR20170140245A (ko) 2017-12-20
EA201792318A1 (ru) 2018-05-31
CY1122572T1 (el) 2021-01-27
SI3285772T1 (sl) 2020-02-28
EP3285772A1 (en) 2018-02-28
GB201506786D0 (en) 2015-06-03
PL3285772T3 (pl) 2020-05-18
HUE047162T2 (hu) 2020-04-28
EP3285772B1 (en) 2019-10-02
US20180092921A1 (en) 2018-04-05
BR112017020591B8 (pt) 2023-05-16
HRP20192273T1 (hr) 2020-03-06
KR102627370B1 (ko) 2024-01-18
US10493074B2 (en) 2019-12-03
SG11201707789YA (en) 2017-11-29
BR112017020591B1 (pt) 2023-02-07
WO2016170014A1 (en) 2016-10-27
MY192972A (en) 2022-09-20
CO2017010573A2 (es) 2018-03-09
EA032432B1 (ru) 2019-05-31
JP6721606B2 (ja) 2020-07-15
MX2017013148A (es) 2018-02-21
PT3285772T (pt) 2020-01-14
AR105552A1 (es) 2017-10-18
JP2018513862A (ja) 2018-05-31
LT3285772T (lt) 2020-01-10
CN107530344A (zh) 2018-01-02
BR112017020591A2 (pt) 2018-07-03
IL254766B (en) 2020-05-31
CA2981631A1 (en) 2016-10-27
ES2763335T3 (es) 2020-05-28
IL254766A0 (en) 2017-12-31
AU2016251236B2 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3227262T3 (da) Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3668509T3 (da) Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3556383T3 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3897672T5 (da) Hbv kombinationsbehandling
DK3666258T3 (da) Fremgangsmåde til behandling af prader-willis syndrom
DK3512506T3 (da) Anvendelse af pridopidin til behandling af retts syndrom
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3445157T3 (da) Udtrækkelig plantebakkeenhed
DK3618845T3 (da) Peptider til behandling af diabetes
DK3177931T3 (da) Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder
DK3377064T3 (da) Orvepitant til behandling af kronisk hoste